Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX1001 gene therapy in APOE4 homozygote Alzheimer's disease
NCT03634007Phase 2Completed
- Sponsor
- Lexeo Therapeutics
- Start
- Nov 2019
- Primary completion
- Nov 2024
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of LX1001 in Alzheimer's disease (AD), sponsored by Lexeo Therapeutics. Started Nov 2019; status: completed.
02
Drugs
LX1001
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03634007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634007.